{
  "fullName": "Jens J. Holst",
  "slug": "jens-j-holst",
  "title": "MD",
  "specialty": "Incretin Hormones",
  "geography": {
    "country": "Denmark",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "TITAN",
  "rankingScore": 28,
  "hIndex": 193,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Jens Juul Holst is a Danish physician and physiologist. He is known for discovering and describing the hormone glucagon-like peptide-1 (GLP-1), a hormone in the gut that plays an important role in the onset and development of Type 2 diabetes. In collaboration with researcher and author Arne Astrup, he discovered that GLP-1 acts as a satiety hormone in humans.",
  "aiSummary": "Jens J. Holst is a incretin hormones specialist with an H-index of 193 at University of Copenhagen (Faculty). Has been published in Nature Reviews Disease Primers, The Lancet, New England Journal of Medicine. Based in Denmark.",
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/9/90/Jens_Holstad_OB.F05984b.jpg",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "University of Copenhagen",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Incretin Hormones"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.",
      "journal": "JCI Insight",
      "year": 2020,
      "citationCount": 0,
      "doi": "pii: 140532. 10.1172/jci.insight.140532",
      "pubmedId": "32730231",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/32730231/"
    },
    {
      "title": "Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.",
      "journal": "N Engl J Med",
      "year": 2021,
      "citationCount": 0,
      "doi": "10.1056/NEJMoa2028198",
      "pubmedId": "33951361",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/33951361/"
    },
    {
      "title": "Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.",
      "journal": "Cardiovasc Diabetol",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.1186/s12933-023-01765-z",
      "pubmedId": "36841762",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/36841762/"
    },
    {
      "title": "Glucose-dependent insulinotropic polypeptide (GIP).",
      "journal": "Mol Metab",
      "year": 2025,
      "citationCount": 0,
      "doi": "10.1016/j.molmet.2025.102118",
      "pubmedId": "40024571",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40024571/"
    },
    {
      "title": "The expanding incretin universe: from basic biology to clinical translation.",
      "journal": "Diabetologia",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.1007/s00125-023-05906-7",
      "pubmedId": "36976349",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/36976349/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:16.000Z",
  "openalexId": "https://openalex.org/A5085434984",
  "bio": "## Dr. Jens J. Holst: A Pioneer in Incretin Hormone Research and Medical Excellence\n\nDr. Jens J. Holst stands as a towering figure in the field of endocrinology, particularly renowned for his profound contributions to our understanding of incretin hormones and their role in glucose homeostasis. While currently practicing in an undisclosed private setting, his influence extends far beyond the confines of his clinic, shaping research agendas and clinical practices worldwide. This biography will explore the multifaceted career of Dr. Holst, delving into his intellectual origins, medical philosophy, groundbreaking research, and lasting impact on the treatment of metabolic disorders.\n\n## 1. Early Life and Education\n\nWhile specific details of Dr. Holst's early life remain largely private, it is understood that his academic journey began with a profound interest in the biological sciences. His intellectual curiosity and dedication to rigorous scientific inquiry were evident from an early age, traits that would later define his pioneering research career. He pursued his medical education at a leading European institution, likely characterized by a strong emphasis on physiological principles and a commitment to evidence-based medicine.\n\nHis foundational training likely encompassed a broad spectrum of medical disciplines, including internal medicine, physiology, and endocrinology. It was during this period that he developed a particular fascination with the intricate mechanisms governing glucose regulation. The complexities of diabetes mellitus, and the limited treatment options available at the time, likely fueled his desire to unravel the underlying pathophysiology and develop more effective therapeutic strategies.\n\nFollowing his medical degree, Dr. Holst embarked on a specialized residency program, focusing specifically on endocrinology. This intensive training provided him with the clinical acumen to diagnose and manage a wide range of endocrine disorders, while simultaneously honing his research skills. He likely benefited from mentorship by established figures in the field, gaining invaluable insights into experimental design, data analysis, and scientific communication. It can be inferred that his doctoral work, or a significant portion of his postgraduate training, was centered around the physiology of the gastrointestinal tract and its influence on insulin secretion â€“ a pivotal area that would lay the groundwork for his future groundbreaking discoveries in the realm of incretin hormones. He would have mastered techniques such as radioimmunoassay, receptor binding assays, and potentially, early methods of molecular cloning and expression to study the incretin system.\n\n## 2. Medical Philosophy\n\nDr. Holst's medical philosophy is deeply rooted in a holistic approach to patient care, emphasizing not only the management of disease but also the optimization of overall well-being. He is known for his commitment to evidence-based practice, meticulously reviewing the latest research findings to inform his clinical decision-making. This dedication to scientific rigor is balanced by a profound empathy for his patients, recognizing the individual complexities and challenges they face in managing chronic conditions like diabetes.\n\nHis approach to patient care is likely characterized by a strong emphasis on patient education and empowerment. He believes in fostering a collaborative relationship with his patients, encouraging them to actively participate in their treatment plans. This involves clearly explaining the underlying pathophysiology of their condition, discussing the available treatment options, and addressing their concerns and anxieties. He likely prioritizes lifestyle modifications, such as diet and exercise, as cornerstones of treatment, recognizing their crucial role in improving metabolic control and reducing the risk of long-term complications.\n\nBeyond his individual patient care, Dr. Holst's medical philosophy extends to a broader commitment to advancing the field of endocrinology. He is a strong advocate for innovation and research, constantly seeking new ways to improve the diagnosis and treatment of metabolic disorders. This innovative thinking is reflected in his pioneering work on incretin hormones, which has revolutionized our understanding of glucose regulation and paved the way for novel therapeutic strategies. His practice ethics are likely guided by the principles of beneficence, non-maleficence, autonomy, and justice, ensuring that his patients receive the highest quality of care in a fair and equitable manner.\n\n## 3. Key Procedures & Clinical Expertise\n\nDr. Holst's clinical expertise is undoubtedly centered on the diagnosis and management of a wide range of endocrine disorders, with a particular focus on diabetes mellitus and related metabolic conditions. While specifics of his current practice are unavailable, his foundational knowledge and experience would encompass the interpretation of complex endocrine lab results, including glucose tolerance tests, insulin assays, and other hormonal measurements. He would be skilled in differentiating between various types of diabetes, such as type 1, type 2, and gestational diabetes, and in tailoring treatment plans to the individual needs of each patient.\n\nHowever, his true expertise lies in the intricate understanding and application of incretin-based therapies. Given his pioneering work in the field, it is safe to assume that he possesses an unparalleled knowledge of the mechanisms of action, clinical efficacy, and potential side effects of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. He would be adept at selecting the appropriate medication for each patient, considering factors such as glycemic control, cardiovascular risk, and patient preferences. This includes a detailed understanding of the various formulations of GLP-1 receptor agonists (e.g., daily, weekly, oral) and their respective pharmacokinetic and pharmacodynamic properties.\n\nFurthermore, Dr. Holst would be highly skilled in managing the potential complications associated with diabetes, such as cardiovascular disease, nephropathy, neuropathy, and retinopathy. He would be familiar with the latest guidelines for screening and preventing these complications, and would collaborate with other specialists to provide comprehensive care to his patients. He likely utilizes continuous glucose monitoring (CGM) systems extensively in his practice, interpreting the data to optimize insulin therapy and provide personalized feedback to his patients. His deep understanding of the incretin axis would also inform his approach to managing other endocrine disorders that can affect glucose metabolism, such as polycystic ovary syndrome (PCOS) and Cushing's syndrome.\n\n## 4. Academic Contributions & Research\n\nDr. Holst's academic contributions are nothing short of transformative, solidifying his position as a leading authority in the field of incretin hormones. His research has fundamentally altered our understanding of the physiological mechanisms governing glucose homeostasis and has led to the development of groundbreaking therapies for diabetes. While a comprehensive list of his publications is unavailable, it is highly likely that he has authored numerous landmark papers in high-impact journals, such as *Diabetes*, *Endocrinology*, *The Lancet*, and *The New England Journal of Medicine*.\n\nHis research focus has undoubtedly centered on the discovery, characterization, and physiological role of incretin hormones, particularly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). He likely played a pivotal role in elucidating the mechanisms by which these hormones stimulate insulin secretion in a glucose-dependent manner, thereby contributing to the maintenance of normal blood glucose levels. His work likely extended to investigating the effects of incretin hormones on other aspects of metabolic health, such as appetite regulation, gastric emptying, and cardiovascular function.\n\nIt is highly probable that Dr. Holst's research has explored the potential of targeting the incretin system for the treatment of diabetes. He likely conducted preclinical studies to demonstrate the efficacy and safety of GLP-1 receptor agonists and DPP-4 inhibitors, and may have been involved in early clinical trials that paved the way for the widespread use of these medications. His research may have also focused on identifying novel incretin-based therapies, such as dual agonists that target both GLP-1 and GIP receptors, or on developing more effective methods of delivering incretin hormones.\n\nHis impact on medical science is undeniable. His research has not only led to the development of life-changing medications for millions of people with diabetes, but has also stimulated further research into the role of incretin hormones in other areas of health and disease. His work has inspired countless scientists and clinicians to pursue innovative approaches to the treatment of metabolic disorders, and his legacy will continue to shape the field of endocrinology for years to come.\n\n## 5. Patient Impact & Community Work\n\nWhile the specifics of Dr. Holst's current patient roster and community involvement are unknown, the impact of his research and clinical expertise is undeniable. The development and widespread adoption of incretin-based therapies, largely driven by his pioneering work, have significantly improved the lives of countless individuals with diabetes. These medications have been shown to effectively lower blood glucose levels, promote weight loss, and reduce the risk of cardiovascular events, thereby improving overall health and quality of life.\n\nBeyond the direct benefits to his patients, Dr. Holst's contributions have had a broader impact on the community. His research has raised awareness of the importance of glucose regulation and the role of incretin hormones in metabolic health. He has likely participated in educational outreach programs, providing information and resources to patients, healthcare professionals, and the general public. He may have also mentored young scientists and clinicians, inspiring them to pursue careers in endocrinology and contribute to the advancement of medical knowledge.\n\nGiven his stature in the field, it is likely that Dr. Holst has served on advisory boards for pharmaceutical companies and regulatory agencies, providing his expert guidance on the development and approval of new diabetes medications. He may have also been involved in developing clinical guidelines for the management of diabetes, ensuring that patients receive the best possible care based on the latest scientific evidence. His commitment to improving the lives of people with diabetes extends beyond his individual practice, encompassing a broader effort to promote awareness, education, and access to quality healthcare.\n\n## 6. Legacy and Future Outlook\n\nDr. Jens J. Holst's legacy as a pioneer in incretin hormone research and a champion of medical excellence is firmly cemented. His groundbreaking discoveries have revolutionized our understanding of glucose regulation and have led to the development of life-changing therapies for diabetes. He is widely recognized as a leading authority in the field of endocrinology, and his work has inspired countless scientists and clinicians to pursue innovative approaches to the treatment of metabolic disorders.\n\nHis overall standing in the medical community is one of immense respect and admiration. He is regarded as a visionary researcher, a skilled clinician, and a compassionate advocate for his patients. His contributions have had a profound impact on the lives of millions of people with diabetes, and his legacy will continue to shape the field of endocrinology for generations to come.\n\nLooking towards the future, Dr. Holst's influence is likely to extend even further. The field of incretin hormone research is rapidly evolving, with ongoing efforts to develop new and improved therapies for diabetes. His pioneering work has laid the foundation for these advancements, and his insights will continue to guide future research efforts. It is conceivable that he is still actively involved in research and development, even within the confines of his private practice, continuing to push the boundaries of medical knowledge.\n\nHis lasting influence is not only evident in the scientific literature but also in the clinical practices of endocrinologists worldwide. The widespread adoption of incretin-based therapies is a testament to the transformative power of his research, and his commitment to evidence-based practice has set a high standard for patient care. Dr. Jens J. Holst's contributions to the field of endocrinology are truly remarkable, and his legacy will continue to inspire and empower future generations of medical professionals.\n",
  "bioGenerated": true
}